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A lysosomal phospholipase A2, LPLA2, was recently characterized and shown to have substrate specificity
for phosphatidylcholine and phosphatidylethanolamine. LPLA2 is ubiquitously expressed but is most highly
expressed in alveolar macrophages. Double conditional gene targeting was employed to elucidate the function
of LPLA2. LPLA2-deficient mice (Lpla2ⴚ/ⴚ) were generated by the systemic deletion of exon 5 of the Lpla2 gene,
which encodes the lipase motif essential for the phospholipase A2 activity. The survival of the Lpla2ⴚ/ⴚ mice
was normal. Lpla2ⴚ/ⴚ mouse mating pairs yielded normal litter sizes, indicating that the gene deficiency did
not impair fertility or fecundity. Alveolar macrophages from wild-type but not Lpla2ⴚ/ⴚ mice readily degraded
radiolabeled phosphatidylcholine. A marked accumulation of phospholipids, in particular phosphatidylethanolamine and phosphatidylcholine, was found in the alveolar macrophages, the peritoneal macrophages, and
the spleens of Lpla2ⴚ/ⴚ mice. By 1 year of age, Lpla2ⴚ/ⴚ mice demonstrated marked splenomegaly and increased
lung surfactant phospholipid levels. Ultrastructural examination of Lpla2ⴚ/ⴚ mouse alveolar and peritoneal macrophages revealed the appearance of foam cells with lamellar inclusion bodies, a hallmark of cellular phospholipidosis. Thus, a deficiency of lysosomal phospholipase A2 results in foam cell formation, surfactant lipid accumulation, splenomegaly, and phospholipidosis in mice.
Previously, a novel enzyme was discovered in the lysosomal
fraction of MDCK cells. The enzyme was characterized as
having ceramide transacylase and phospholipase A2 activity
(3). The enzyme was purified, cloned, and named lysosomal
phospholipase A2 (LPLA2) (12). Characteristics of the enzyme include a pH optimum of 4.5 and calcium independence.
In addition, phosphatidylcholine and phosphatidylethanolamine are preferentially favored as substrates for the phospholipase A2. The enzyme is highly homologous with lecithin cholesterol acyltransferase and is phylogenetically related to a
large group of plant phospholipases (15). Most recently, the
phospholipase activity was demonstrated as highly expressed in
alveolar macrophages, suggesting a potential role for LPLA2
in the phospholipid catabolism of pulmonary surfactant (1).
LPLA2-deficient mice were generated to further evaluate the
biological function of LPLA2.
In the present study, double conditional targeted mice were
generated, and the targeted gene was modified using Cre/loxP
and Flp/FRT recombination systems. Lpla2-deficient mice
were generated in which exon 5 of the Lpla2 gene, which
encodes the lipase motif essential for Lpla2 activity, was systemically deleted. The resultant Lpla2⫺/⫺ mice showed no
LPLA2 activity, developed normally, and were characterized
by a marked accumulation of phospholipid in their alveolar
macrophages, peritoneal macrophages, and spleens at an early
age. Increased lung surfactant phospholipid and splenomegaly
were observed in mice by 1 year of age.

MATERIALS AND METHODS
Reagents. Synthetic phospholipids, including 1,2-dioleloyl-sn-glycero-3-phosphorylcholine (DOPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphorylcholine
(POPC), and 1,2-dimyristoleoyl-sn-glycero-3-phosphocholine (14:1-14:1 PC);
1,2-dipentadecanoyl-sn-glycero-3-phosphoethanolamine (15:0-15:0 PE); 1,2-dipenta-decanoyl-sn-glycero-3-phosphoglycerol (15:0-15:0 PG); 1,2-dimyristoyl-snglycero-3-phosphoserine (14:0-14:0 PS); 1-heptadecanoyl-2-hydroxyl-sn-glycero3-phos-phocholine (17:0 lysoPC); and N-heptadecanoyl ceramide (N17:1 Cer)
were purchased from Avanti Polar Lipids, Inc. (Alabaster, AL). Deuterated
palmitic acid (d4-16:0 FA) was purchased from Cambridge Isotope Laboratories
(Andover, MA). Dicetyl phosphate was purchased from Sigma (St. Louis, MO),
1-palmitoyl-2-[14C]oleoyl-sn-3-glycero-phosphorylcholine (25 Ci/ml) was from
Amersham Biosciences (Piscataway, NJ), and N-acetyl-D-erythro-sphingosine
(NAS) was from Matreya (Pleasant Gap, PA). Bicinchoninic acid protein assay
reagent was obtained from Pierce Chemical (Rockford, IL).
Generation of Lpla2 double conditional targeted mice. The genome sequence
containing the Lpla2 gene was obtained from screening the Resgen CJ7 embryonic stem (ES) cell line BAC clone library (Invitrogen, Carlsbad, CA). A SmaISacI fragment of approximately 8,450 bp of the Lpla2 gene was subcloned into
the pUC vector. In a previous report it was shown that the lipase motif, located
within exon 5, is essential for LPLA2 enzyme activity (12). Therefore, to create
the conditional null allele, the SpeI-DraI region containing exon 5 was floxed
with two loxP sites and then inserted into the vector (Fig. 1A). The PGK-neo
cassette flanked with two FRT sites was inserted at the SpeI site in the intron
between exons 4 and 5 in reverse orientation. The targeting vector was sequenced to ensure that no mutation had been introduced and then was linearized
by NdeI digestion and electroporated into CJ7 ES cells. Homologous recombinant clones were obtained from G418-resistant colonies screened at a frequency
of 20%. The G418-resistant clones were screened by PCR using primers inside
and outside the targeting construct. A correctly targeted clone was injected into
C57BL/6 blastocysts. The chimeric mice were mated with C57BL/6 to obtain
heterozygous mice carrying the targeted allele. Mice carrying the targeted allele
were mated with flp1 mice (stock no. 3800; The Jackson Laboratory) to delete
the neo cassette. The conditional heterozygous mice were then mated with EIIa
Cre mice of C57BL/6 background (stock no. 3724; The Jackson Laboratory) to
excise the region containing exon 5. The heterozygous mice carrying the null
allele were mated to generate homozygous (⫺/⫺), heterozygous (⫹/⫺), and
wild-type (⫹/⫹) littermates of the Lpla2 null allele. Homologous recombination
at the null allele was screened by PCR (Fig. 1B). Genomic DNA was extracted
from the tails of the mice. The PCR primers were as follows: a, 5⬘-CAGGGTA
GCTCACAACTCTTTG-3⬘; b, 5⬘-CAAAGCTCTGGACTGTTTTCCTGC-3⬘; c,
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5⬘-GAATTCCTAGACCCCAGCAAGAAGAATGTG-3⬘; and d, 5⬘-CCCTCCC
CAGAGATGGATATTT-3⬘. Primers a and d generated 5.8-kb and 5.5-kb products from a wild-type allele and a null allele by PCR, respectively. Primers b and
c generated 4.1-kb and 3.8-kb products from a wild-type allele and a null allele
by PCR, respectively. The PCR amplification employed 35 cycles with steps at
94°C for 30 s, 60°C for 30 s, and 72°C for 3 min, which was extended 20 s every
cycle for the last 25 cycles using ExTaq DNA polymerase (Takara Bio, Shiga,
Japan). The PCR products were subjected to electrophoresis, purification, and
sequencing. To confirm wild-type, conditional, and null alleles, the PCR with primers c and d using rTaq polymerase (Takara Bio) employed 35 cycles with steps at
94°C for 30 s, 60°C for 30 s, and 72°C for 1 min. The product sizes were 1,212, 1,444,
and 894 bp for the wild-type, conditional, and null alleles, respectively.

Reverse transcription-PCR analysis. Total RNA was isolated from each
mouse organ using Trizol reagent (Invitrogen) followed by purification using an
RNeasy kit (QIAGEN, Valencia, CA). The total RNA was used to synthesize
cDNA with oligo(dT)12-18 primers in the SuperScript First-Strand synthesis system (Invitrogen). Primers used for PCR were 5⬘-ATGGATCGCCATCTC-3⬘
(forward) and 5⬘-TCAAGGTTCCAGAAGCACACGTTT-3⬘ (reverse). PCR
was performed using rTaq polymerase with the conditions described above. PCR
products were purified and sequenced.
Isolation of mouse macrophages and tissues. All mice were housed in specificpathogen-free conditions and used at 2 to 12 months of age. After anesthesia
with CO2 inhalation, the organs were isolated. For isolation of alveolar macrophages, the tracheae were cannulated and the lungs were lavaged with phos-
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FIG. 1. A. Strategy for producing allelic series of mutations at the Lpla2 locus. The partial map of the murine Lpla2 locus is displayed.
Horizontal lines and open boxes with numbers represent introns and Lpla2 exons, respectively. Vertical lines represent restriction sites: M, SmaI;
P, SpeI; D, DraI; A, SacI. The Lpla2 double conditional targeting vector was designed. Shaded triangles represent loxP sites flanking the Lpla2
gene exon 5, and shaded half-circles represent FRT sites flanking the neomycin resistance cassette (PGK neo). The targeted allele was generated
by homologous recombination. The primers used for PCR are shown as horizontal arrows with letters. The conditional allele was generated by
Flp-mediated excision. The heterozygous mice carrying targeted alleles were mated with FLP1 transgenic mice to delete the neo cassette. The null
allele was generated by Cre-mediated excision. The heterozygous mice carrying conditional alleles were mated with EIIa Cre transgenic mice to
delete exon 5. B. Genotype analysis by PCR. Genomic DNA was extracted from mouse tail, and PCR was performed to evaluate homologous
recombination. The primers a and d as well as b and c were used for upper panel and lower panel assays, respectively. TV indicates targeting vector.
M indicates molecular marker. C. Reverse transcription-PCR assay. Total RNAs were isolated from various mouse organs and synthesized cDNA.
PCR was performed using primers which are able to cover the Lpla2 coding region. M, molecular marker _174 RF DNA/HaeIII; H, heart; Li,
liver; S, spleen; K, kidney; T, thymus; B, brain; Lu, lung. D. Immunoblots of Lpla2 from the alveolar macrophages obtained from Lpla2⫹/⫹,
Lpla2⫹/⫺, and Lpla2⫺/⫺ mice. Alveolar macrophages were isolated from mice as described in Materials and Methods, and the soluble fraction was
separated by gel electrophoresis as previously described (1). A rabbit anti-LPLA2 polyclonal antibody (100RTSRATQFPD109) was used for
detection. E. Transacylase activity in the soluble fraction of alveolar macrophages obtained from Lpla2⫹/⫹, Lpla2⫹/⫺, and Lpla2⫺/⫺ mice. Each
soluble fraction (3 g of protein) obtained from 3-month-old Lpla2⫹/⫹, Lpla2⫹/⫺, and Lpla2⫺/⫺ mouse alveolar macrophages was incubated for
30 min at 37°C in citrate buffer, pH 4.5, with 40 M NAS in liposomal form, and formation of 1-O-acyl-NAS was determined as described in
Materials and Methods. The transacylase specific activities for the Lpla2⫹/⫹, Lpla2⫹/⫺, and Lpla2⫺/⫺ mouse alveolar macrophages were 3.9
g/min/mg protein, 2.08 g/min/mg protein, and undetected, respectively. w/o, without; Fr., fraction.
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Lipid analysis. Lipids were extracted from tissues, alveolar macrophages,
peritoneal macrophages, and bronchoalveolar lavage fluid of 3-month-old mice
by the partially modified method of Bligh and Dyer (5). The phospholipid
content was measured by the method of Ames (4). Individual phospholipids were
separated by high-performance thin-layer chromatography and quantified as
described above. Disaturated phosphatidylcholine in samples was isolated by the
method of Mason et al. (13). Whole-lipid extract (20 to 100 nmol as phospholipid) was dried under a stream of nitrogen gas. The dried lipid was dissolved in
500 l of 6.2 mg/ml osmium tetraoxide in carbon tetrachloride and incubated for
15 min at room temperature. The reaction mixture was dried under a stream of
nitrogen gas, redissolved in 500 l of chloroform/methanol (20:1, vol/vol), and
applied to an alumina column (0.6 g of activated neutral aluminum oxide, 150
mesh) preequilibrated with chloroform/methanol (20:1, vol/vol). The column was
washed with 8 ml of chloroform/methanol (20:1, vol/vol). Disaturated phosphatidylcholine was eluted with 4 ml of chloroform/methanol/7 M ammonium hydroxide (70:30:2, vol/vol), and the eluted fraction was dried under a stream of
nitrogen gas. Phosphate content was determined by the method of Ames (4).
For electrospray ionization/mass spectrometry (ESI/MS), lipid extraction from
alveolar macrophage preparations (0.1 to 0.5 mg of proteins) was performed
using a modified method of Bligh and Dyer as previously described in detail (11).
Briefly, internal standards, including 14:0–14:0 phosphatidylserine (8.0 nmol/mg
protein), 15:0-15:0 phosphatidylglycerol (6 nmol/mg protein), 15:0-15:0 PE (13
nmol/mg protein), 14:1-14:1 PC (20 nmol/mg protein), 17:0 lysoPC (2 nmol/mg
protein), N17:1 ceramide (0.24 nmol/mg protein), and d4-16:0 fatty acid (12
nmol/mg protein), were added to each individual sample based on protein concentration. Lipids from each sample were extracted against 2 ml of 50 mM LiCl
twice, back extracted against 2 ml of 10 mM LiCl twice, filtered with a 0.2-m
polytetrafluoroethylene syringe filter, and finally stored in chloroform/methanol
(1:1, vol/vol) at a concentration of 600 l/mg protein. The lipid extracts were
finally flushed with nitrogen, capped, and stored at ⫺20°C for ESI/MS analyses
(typically within 1 week). Each lipid solution was further diluted approximately
10-fold just prior to infusion and lipid analysis. To this diluted lipid solution,
LiOH (50 nmol/mg of protein) was added just prior to performing further lipid
analyses in both negative- and positive-ion modes.
ESI/MS analyses were performed utilizing a triple-quadrupole mass spectrometer (ThermoElectron TSQ Quantum Ultra, San Jose, CA) equipped with an
electrospray ion source as described previously (11). Typically, a 1-min period of
signal averaging in the profile mode was employed for each MS spectrum, and a
1- to 2-min period of signal averaging for each MS/MS spectrum was used.
Global analyses of lipid extracts were performed by shotgun lipidomics as described previously (9, 10). Quantitation of each individual molecular species of
lipid classes were performed using a two-step process, as described in detail
previously (8, 9).
Degradation of 1-palmitoyl-2-[14C]oleoyl-sn-glycero-3-phosphorylcholine
(POPC) by alveolar macrophages. Alveolar macrophages (1.3 ⫻ 106 cells) obtained from 3- to 5-month-old Lpla2⫹/⫹ and Lpla2⫺/⫺ mice were seeded into a
35-mm dish containing 2 ml of RPMI 1640 medium (Invitrogen) containing 1⫻
antibiotic-antimycotic and followed by incubation at 37°C in a humidified atmosphere of 5% CO2 in air. After 90 min, nonadherent cells were removed by
washing with PBS. The adherent cells were incubated with 2.1 ml of RPMI 1640
medium containing 320 M (0.25 Ci/ml) 14C-labeled POPC in liposomes consisting of POPC/dicetyl phosphate (10:1 molar ratio) for 4 h at 37°C. After the
incubation, the cells were washed three times with 2 ml of cold PBS and fixed
with 1 ml of cold methanol. The fixed cells were scraped and transferred into a
glass tube. An additional 1 ml of methanol was used to recover the remaining
cells in the dish. The cell suspension was mixed with 1 ml chloroform plus 0.8 ml
of 0.9% NaCl and sonicated in a water bath sonicator briefly and kept for 1 h at
room temperature. The mixture was centrifuged for 30 min at 2,000 ⫻ g at room
temperature, and the supernatant was transferred into a long glass tube. The
supernatant was mixed and vortexed with 3 ml of chloroform plus 0.8 ml of 0.9%
NaCl and centrifuged for 5 min at 800 ⫻ g. The lower layer was washed with 2
ml of methanol plus 1.6 ml of 0.9% NaCl, centrifuged for 5 min at 800 ⫻ g, and
washed again with 2 ml of methanol plus 1.6 ml of water. The resultant lower
layer was transferred into another glass tube and dried under a stream of
nitrogen gas. The dried lipid was dissolved in 100 l of chloroform/methanol
(2:1, vol/vol). Half of the lipid extract was applied to an HPTLC plate and
developed in a solvent system consisting of chloroform/acetic acid (9:1, vol/vol)
or chloroform/methanol/water (60:35:8, vol/vol/vol). After development, the
plate was dried, sprayed with ENHANCE, and exposed on X-ray film at ⫺80°C
for 4 days.
Nucleotide sequence accession number. The genome sequence containing the
Lpla2 gene has been submitted to GenBank under accession number AY179884.
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phate-buffered saline (PBS) containing 0.5 mM EDTA. Peritoneal macrophages
were obtained by lavage of the peritoneal spaces with PBS containing 0.5 mM
EDTA. After being counted, cells were suspended in RPMI 1640 medium containing 1⫻ antibiotic-antimycotic solution (Invitrogen) and plated in culture
dishes, followed by incubation at 37°C in a humidified atmosphere of 5% CO2 in
air. Nonadherent cells were removed by washing with PBS. Under these conditions, the recovered cells were greater than 90% macrophages as measured by
Wright-Giemsa and anti-CD68 staining. The University of Michigan Committee
on the Use and Care of Animals approved all experiments.
Electron microscopy. Fresh tissue was minced into 1-mm cubes, and alveolar
and peritoneal lavage cells were collected and then fixed by immersion in 4%
glutaraldehyde, 0.1 M sodium cacodylate buffer (pH 7.3). The sample was postfixed with osmium tetroxide before embedding in Epon. One-micrometer sections, stained with toluidine blue, were screened by light microscopy to select
cross-sections for ultrastructural study. Thin sections were stained with uranyl
acetate and lead citrate before examination with a Philips 400T transmission
electron microscope. Representative photomicrographs were selected.
Preparation of cell homogenate and soluble fraction from mouse alveolar and
peritoneal macrophages and tissues. For the preparation of the soluble fractions
of alveolar macrophages and peritoneal macrophages, the cells were allowed to
adhere to 35-mm culture dishes, washed three times with 2 ml of cold PBS,
scraped with a small volume of PBS, and transferred into 15-ml plastic tubes. The
cells were collected by centrifugation at 800 ⫻ g for 10 min at 4°C and resuspended with 0.4 to 1.0 ml of cold 0.25 M sucrose, 10 mM HEPES (pH 7.4), 1 mM
EDTA. The cell suspension was disrupted five times with a probe-type sonicator
for 10 s at 0°C to obtain the cellular homogenate. The homogenate was centrifuged for 1 h at 100,000 ⫻ g at 4°C. The resultant supernatant was passed through
a 0.2-m filter and used as a soluble fraction. For the preparation of soluble
fractions of mouse tissues, each organ was washed with cold PBS, weighed, and
homogenized by a Potter Elvehjem homogenizer with cold 0.25 M sucrose, 10
mM HEPES (pH 7.4), 1 mM EDTA. The homogenate was centrifuged for 10
min at 600 ⫻ g at 4°C. The resultant supernatant was sonicated with a probe-type
sonicator for 10 s five times at 0°C and centrifuged for 1 h at 100,000 ⫻ g at 4°C.
The supernatant was passed through a 0.2-m filter and used as a soluble
fraction.
Enzyme phospholipase A2/transacylase assay. Phospholipids, DOPC and PE,
and N-acetylsphingosine were used in the assay system as donor and an acceptor,
respectively, of an acyl group. The transacylase activity by LPLA2 was determined by analysis of 1-O-acyl-N-acetylsphingosine formation rate. The reaction
mixture consisted of 45 mM sodium citrate (pH 4.5), 10 g/ml bovine serum
albumin, and 40 M N-acetylsphingosine incorporated into phospholipid liposomes (DOPC/PE/dicetyl phosphate/N-acetylsphingosine [5:2:1:2 molar ratio])
and soluble fractions (0.7 to 10 g) in a total volume of 500 l. The reaction was
initiated by adding the soluble fraction, kept for 5 to 60 min at 37°C, and
terminated by adding 3 ml of chloroform/methanol (2:1) plus 0.3 ml of 0.9%
(wt/vol) NaCl. The mixture was centrifuged for 5 min at room temperature. The
resultant lower layer was transferred into another glass tube and dried under a
stream of nitrogen gas. The dried lipid dissolved in 40 l of chloroform/methanol
(2:1) was applied on an high-performance thin-layer chromatography (HPTLC)
plate and developed in a solvent system consisting of chloroform/acetic acid
(9:1). The plate was dried and soaked in 8% (wt/vol) CuSO4, 5H2O, 6.8%
(vol/vol) H3PO4, 32% (vol/vol) methanol. The wet plate was briefly dried with a
hair dryer and charred for 15 min in a 150°C oven. The plate was scanned, and
NIH-image 1.62 was used to quantify the reaction products.
The following protocol was used for the phospholipase A2 assay without
N-acetylsphingosine as an acceptor. The reaction mixture contained 48 mM
sodium citrate (pH 4.5), 10 g/ml bovine serum albumin, liposomes (130 M
phospholipid), and 1.77 g/ml of the soluble fraction obtained from Lpla2⫹/⫹ or
Lpla2⫺/⫺ mouse alveolar macrophages in 500 l of total volume. The liposomes
consisted of 1-oleoyl-2-palmitoyl-sn-glycero-3-phosphocholine and dicetylphosphate in the molar ratio 10:1, with a trace of 1-palmitoyl-2-1-[14C]palmitoyl-Lsn-glycero-3-phosphocholine (2.8 ⫻ 105 cpm/assay). The reaction was initiated by
adding 20 l of each soluble fraction or sucrose buffer, kept for 15, 30, and 45
min at 37°C, and terminated by the addition of 3 ml of chloroform/methanol
(2:1) plus 300 l of 0.9% NaCl. The resultant lower layer was transferred into a
small glass tube and dried under a stream of nitrogen gas. The dried lipid was
redissolved with chloroform/methanol (2:1) and applied to an HPLTC plate. The
plate was developed in a solvent system consisting of chloroform/methanol/
pyridine (98:2:0.5). After development, the plate was dried, sprayed with
ENHANCE, and exposed on X-ray film at ⫺80°C for 20 h. In the study using
lung tissue, the same reaction was initiated by the addition of 10 g of lung
soluble fraction and kept for 30, 60, and 90 min at 37°C.
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in Lpla2⫺/⫺ mouse alveolar macrophages (Fig. 1E). The
transacylase activity from Lpla2⫹/⫺ mouse alveolar macrophages was approximately 50% of that of the Lpla2⫹/⫹ mouse
alveolar macrophages. The deficiency of the enzyme activity in
the soluble fraction of the Lpla2⫺/⫺ mouse was also observed
in other cells and tissues, including peritoneal macrophages,
heart, lung, liver, spleen, kidney, thymus, and brain (data not
shown).
Phospholipid degradation in alveolar macrophages. Many
classes of phospholipase A2 exist (17). On the one hand, the
absence of ceramide transacylase activity in alveolar macrophages might not necessarily mean that cellular phospholipase
A2 activity would be impaired as well. On the other hand,
Lpla2 is very highly expressed in alveolar macrophages and
might represent the major phospholipase A2 activity. Therefore, the degradation of PC was more extensively evaluated in
the mouse alveolar macrophages. A choice of substrate was
required. When previously studied, Lpla2 was observed to recognize 1,2-dipalmitoyl-sn-glycero-3-phosphorylcholine (DPPC), a
major component of pulmonary surfactant lipid, when presented
as a substrate in DOPC/DPPC liposomes (1). However, Lpla2
demonstrated greater activity toward DOPC than DPPC. Furthermore, DPPC led to a reduction of the enzyme activity on
DOPC in DOPC/DPPC liposomes. These results suggested that
unsaturated phospholipids are better substrates than saturated
phospholipids and may provide a preferable environment in the
Lpla2 reaction.
The transfer of oleic acid to N-acetyl-sphingosine and the
release of oleic acid from POPC by the soluble fraction obtained from Lpla2⫹/⫹ mouse alveolar macrophages were observed when POPC/dicetyl phosphate/N-acetyl-sphingosine liposomes were used (Fig. 2A). The transacylase activity in the
POPC liposome system was comparable to that observed with
the DOPC/dicetyl phosphate/N-acetyl-sphingosine liposome
system. These results were further evaluated with the use of
alveolar macrophages and radiolabeled POPC. Using 1-palmitoyl-2-[14C]oleoyl-sn-glycero-3-phosphorylcholine, the phospholipase A2 activity was compared between the lungs and
alveolar macrophages of Lpla2⫹/⫹ and Lpla2⫺/⫺ mice (Fig.
2B). When assayed at pH 4.5, the phospholipase A2 activity in
the wild-type lung was 1.10 nmol/min/mg protein but was only
0.072 nmol/min/mg protein in the Lpla2 null mice. The alveolar macrophage activity was 18.6 nmol/min/mg protein versus
0.43 nmol/min/mg protein in the wild-type and knockout mice,
respectively. The higher specific activity of Lpla2 in the alveolar macrophages compared to that of the whole lung is consistent with the prior observation reported for Lpla2 assayed as
ceramide transacylation (1).
The products of the phospholipase A2 reaction were further
evaluated. The radioactive oleic acid released from POPC was
readily detected in the lipid extract obtained from the
Lpla2⫹/⫹ mouse alveolar macrophages treated with 1-palmitoyl-2-[14C]oleoyl-sn-glycero-3-phosphorylcholine/dicethyl phosphate liposomes (Fig. 2C). On the contrary, there was no radioactive oleic acid detected in the lipid extract obtained from
the Lpla2⫺/⫺ mouse alveolar macrophages treated with 14Clabeled POPC liposomes. The total radioactivity found in the
lipid extract, obtained from the Lpla2⫺/⫺ mouse alveolar macrophages, was approximately one-half of the amount from the
Lpla2⫹/⫹ mouse macrophages. The radioactivity of oleic acid
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Generation of LPLA2-deficient mice. To create Lpla2 null
mice, a targeting vector was designed and constructed containing two loxP sites and two FRT sites with a PGK-neo cassette
placed between the FRT sites for modification by use of Cre/
loxP and Flp/FRT recombination systems (Fig. 1A). Exon 5,
which encodes the lipase motif essential for Lpla2 activity, was
floxed with two loxP sites and then inserted into the vector. CJ7
ES cells were electroporated with the linearized targeting vector. Homologous recombinant clones were obtained from
G418-resistant colonies screened at a frequency of 20%. A
correctly targeted clone was injected into C57BL/6 blastocysts.
The chimeric mice were mated with C57BL/6 mice to obtain
heterozygous mice carrying the targeted allele.
Mice carrying the targeted allele were found to be normal
and fertile. However, homozygous offspring from heterozygous
pairs showed a modest reduction of Lpla2 activity in the soluble fraction of brain (data not shown). This finding suggested
that the neo cassette inclusion affected Lpla2 expression. flp1
transgenic mice express FLP recombinase in the early embryo
under the control of the human ␤-actin promoter. Mice with
the targeted allele were mated with flp1 transgenic mice to
delete the neo cassette. The allele in which the neo cassette was
deleted by using an Flp/FRT recombination system is termed
the “conditional allele.” Mice carrying the conditional allele
were normal in appearance and were fertile. The Lpla2 enzyme activity in the homozygous mice carrying the conditional
allele was found to be the same as that of wild-type mice (data
not shown). EIIa Cre transgenic mice express Cre recombinase
in the one-cell zygote stage of embryo development under the
control of the adenovirus EIIa promoter. Heterozygous mice
carrying the conditional allele were mated with EIIa Cre transgenic mice to excise the region containing exon 5. The resultant heterozygous mice carrying the null allele were mated
together to generate Lpla2⫺/⫺, Lpla2⫹/⫺, and Lpla2⫹/⫹ littermates. Homologous recombination at the null allele was
screened by PCR (Fig. 1B). The predicted product from the
deletion of the loxP site flanking region was detected in both
Lpla2⫺/⫺ and Lpla2⫹/⫺ but not in the Lpla2⫹/⫹ mice.
Lpla2⫹/⫺ mice were viable and fertile. They produced an
average of 8.7 pups per litter with a normal Mendelian frequency, indicating no selective fetal or neonatal loss of homozygous pups. Survival of the Lpla2⫺/⫺ mice was normal.
Lpla2⫺/⫺ mating pairs gave normal litter sizes (8.5 pups per
litter), indicating that the gene deficiency did not grossly impair fertility or fecundity. Screening of Lpla2 mRNA expression in seven organs from Lpla2⫺/⫺ mice demonstrated the
deletion of exon 5 in each organ (Fig. 1C), indicating that the
deletion was systemic.
An immunoblot was performed on the protein extracts from
alveolar macrophages of Lpla2⫺/⫺, Lpla2⫹/⫺, and Lpla2⫹/⫹
mice using a previously generated rabbit polyclonal antibody
raised to mouse Lpla2 peptide (100RTSRATQFPD109) (1). A
single band at a molecular mass of ca. 44 kDa was observed in
blots from Lpla2⫹/⫹ and Lpla2⫹/⫺ macrophages. However, no
protein was detected from Lpla2⫺/⫺ alveolar macrophages
(Fig. 1D). The Lpla2 enzyme activities were also compared
among genotypes. The transacylase activity, as measured by
the formation of 1-O-acyl-N-acetylsphingosine, was absent
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recovered from the TLC plate was 260 cpm and 50 cpm for
Lpla2⫹/⫹ and Lpla2⫺/⫺ mouse macrophages, respectively (Fig.
2C). Additionally, the released radioactive oleic acid was comparably low (40 cpm on the TLC plate) when the 14C-labeled
POPC liposomes were incubated with the cultured medium
without alveolar macrophages. Thus, 10 times less radioactive
oleic acid was released from the Lpla2⫺/⫺ mouse alveolar
macrophages compared to that released from the Lpla2⫹/⫹
mouse macrophages. Therefore, most of the oleic acid released
from POPC in the Lpla2⫹/⫹ mouse alveolar macrophages was
due to Lpla2 activity and not an alternative phospholipase A2.
Interestingly, the radioactive lysoPC was detected in
Lpla2⫹/⫹ and Lpla2⫺/⫺ alveolar macrophages. This metabolite, labeled in the sn-2 position, is produced by phospholipase
A1. The radioactivity of lysoPC was 150 cpm and 100 cpm,
respectively, for Lpla2⫹/⫹ and Lpla2⫺/⫺ mouse alveolar macrophages. These results indicate that the degradation of phos-

pholipid in Lpla2⫺/⫺ mouse alveolar macrophages is most
greatly impaired due to a lack of phospholipase A2 activity.
Phospholipid accumulation in the Lpla2ⴚ/ⴚ mouse. The
phospholipid content and profile in alveolar and peritoneal
macrophages and other tissues of 3-month-old Lpla2⫹/⫹ and
Lpla2 ⫺/⫺ mice were next examined. The total phospholipid
content of the Lpla2⫺/⫺ mouse alveolar macrophages was
more than two times higher than that of the Lpla2⫹/⫹ mouse
alveolar macrophages. Thin-layer chromatography of the lipid
extract of the alveolar macrophages showed a marked accumulation of both PE and PC in the Lpla2⫺/⫺ mouse (see the
supplemental material). PE and PC levels were four times and
two times higher by scanning in the Lpla2⫺/⫺ versus Lpla2⫹/⫹
mouse cells, respectively. Phosphatidylserine, phosphatidylinositol, and sphingomyelin levels were no different, consistent
with the known specificity of Lpla2 for PC and PE. The total
phospholipid content in the Lpla2⫺/⫺ peritoneal macrophages
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FIG. 2. Lpla2 activities on unsaturated phosphatidylcholines by Lpla2⫹/⫹ and Lpla2⫺/⫺ mice. A. Transacylase activities of Lpla2 on two
different phosphatidylcholines. The soluble fraction (2 g of protein) obtained from 3-month-old Lpla2⫹/⫹ mice was incubated for a suitable time
period at 37°C in citrate buffer, pH 4.5, with 40 M NAS incorporated into phospholipid liposomes (DOPC or POPC/dicetyl phosphate/NAS [7:1:2
molar ratio]), and formation of 1-O-oleoyl-NAS was determined as described in Materials and Methods. The left panel shows the TLC. The
time-dependent formation of 1-O-oleoyl-NAS from DOPC or POPC/dicetyl phosphate/NAS liposomes by the soluble fraction in Lpla2⫹/⫹ and
Lpla2⫺/⫺ mice. The experiment is representative of three experiments with comparable results. (B) Comparison of phospholipase A2 activities in
the lungs and alveolar macrophages of Lpla2⫹/⫹ and Lpla2⫺/⫺ mice. Phospholipase A2 activities were measured as described in Materials and
Methods using 1-palmitoyl-2-[14C]oleoyl-sn-glycero-3-phosphorylcholine. OA denotes oleic acid. C. Degradation of 1-palmitoyl-2-[14C]oleoyl-snglycero-3-phosphorylcholine by alveolar macrophages. Alveolar macrophages (1.3 ⫻ 106 cells) obtained from 3-month-old Lpla2⫹/⫹ and Lpla2⫺/⫺
mice were incubated with 14C-labeled POPC/dicetyl phosphate (10:1 molar ratio) liposomes for 4 h at 37°C. After the incubation, the cellular lipid
was extracted as described in Materials and Methods. Lipid extract was applied to an HPTLC and developed in a solvent system consisting of
chloroform/acetic acid (9:1) (left) or chloroform/methanol/water (60:35:8) (right). After the development, the plate sprayed with ENHANCE was
exposed on an X-ray film at ⫺80°C. LysoPC indicates lysophosphatidylcholine. AMs, alveolar macrophages.
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TABLE 1. ESI/MS analysis of alveolar macrophage lipids
from 1-year-old mice
Lipid

Lipid levela (nmol/mg protein)
by phenotype
Lpla2⫹/⫹

Phosphatidylcholine
16:0 Phosphatidylcholineb

1.2

538
374
2.3

Phosphatidylethanolamine
Plasmalogen
phosphatidylethanolaminec

250
173

524
414

Sphingomyelin
Phosphatidic acid
Phosphatidylglycerol
Ceramide
Free fatty acid

87.4
0.74
79.8
1.87
124

76.0
0.26
129.0
2.24
155

a
Lipid levels are derived from pooled samples of six mice (three male and
three female) from each group. 16:0 designates the presence of palmitoyl containing phosphatidylcholine.
b
Percent 16:0 PC for Lpla2⫹/⫹ mice, 65.0; for Lpla2⫺/⫺ mice, 69.6.
c
Percent plasmalogen phosphatidyl-ethanolamine for Lpla2⫹/⫹ mice, 69.2; for
Lpla2⫺/⫺ mice, 78.9.

(305 nmol of phospholipid/mg of protein) was 40% higher than
that of the Lpla2⫹/⫹ peritoneal macrophages (223 nmol of
phospholipid/mg of protein). A similar change in phospholipid
profile was observed in the Lpla2⫺/⫺ peritoneal macrophages.
ESI/MS analysis was used to quantify the lipid content of the
Lpla2⫹/⫹ and Lpla2⫺/⫺ alveolar macrophages. Alveolar macrophages were isolated from 12-month-old mice, and internal
standards consisting of 14:0-14:0 phosphatidylserine, 15:0-15:0
phosphatidylglycerol, 15:0-15:0 phosphatidylethanolamine,
14:1-14:1 phosphatidylcholine, 17:0 lysophosphatidylcholine,
N17:1 ceramide, and d4-16:0 fatty acid were added to each
individual sample based on protein concentration. Marked increases in PC and PE were detected in the null mouse macrophages (Table 1; also see the supplemental material). By contrast, no increase in sphingomyelin or phosphatidic acid was
measured. Lysophosphatidylcholine content increased in the
null mouse macrophages. However, the total lysophosphatidylcholine concentration was less than 1% of that of phosphatidylcholine. In wild-type mouse macrophages, 65% of the phosphatidylcholine had one or more fatty acids consisting of the
16:0 palmitic acid. Null mice demonstrated a fractional accumulation of saturated species of PC that was proportionate to
that found in the wild-type cells (see the supplemental material). These data are consistent with the recognition of saturated species of phosphatidylcholine by Lpla2.
Histologic analysis of alveolar and peritoneal macrophages.
Histology was obtained on the lung and major organs of
1-year-old wild-type and null mice. Two marked changes
were observed by light microscopy of the lungs. First, alveolar macrophages were present in greater numbers and were
larger in size. Second, a mononuclear cell infiltrate was
observed in association with both airways and blood vessels
(Fig. 3A and B).
Electron microscopy was performed on alveolar and peritoneal macrophages obtained from 3-month-old Lpla2⫺/⫺ and

DISCUSSION
We successfully generated Lpla2⫺/⫺ mice using a double
conditional targeting system. Lpla2⫺/⫺ mice generated by the
systemic deletion of exon 5 of the Lpla2 gene, which encodes
the lipase motif essential for lysosomal phospholipase A2 activity, were healthy at birth and fertile. Lpla2⫺/⫺ mice showed
no systemic lysosomal phospholipase A2 activity and a characteristic accumulation of PE and PC in alveolar macrophages,
peritoneal macrophages, and spleen. A similar trend in the
phospholipid profile was also observed in tissues such as liver
and lung but with less accumulation. The selective accumulation of PE and PC in Lpla2⫺/⫺ mice is consistent with the
previously reported substrate specificity of Lpla2. Both phospholipids are preferred substrates of Lpla2 (2). Electron microscopy revealed the presence of excessive lamellar inclusion
bodies in Lpla2⫺/⫺ alveolar and peritoneal macrophages. This
foam cell phenotype is characteristic of cellular phospholipidosis (6).
Phospholipidosis is a generalized condition observed in both
animals and humans that is characterized by the appearance of
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Lysophosphatidylcholine

283
184

Lpla2⫺/⫺

Lpla2⫹/⫹ mice to confirm the presence of phospholipidosis.
The alveolar macrophages from the Lpla2⫺/⫺ mice were markedly larger than those from the Lpla2⫹/⫹ mice. Numerous
lamellar inclusion bodies, indicative of cellular phospholipidosis, were observed in the Lpla2⫺/⫺ mouse alveolar macrophages (Fig. 4B). However, such lamellar inclusion bodies were
only rarely present in the Lpla2⫹/⫹ cells (Fig. 4A). A similar but
less robust change was also observed in the peritoneal macrophages (Fig. 4C and 4D). The increase in phospholipid accumulation corresponds to the presence of lamellar inclusions
and cellular phospholipidosis.
The phospholipid content of the mouse lung and lavage fluid
was measured to ascertain if the development of alveolar foam
cells was associated with an increase in total phospholipid
content (Table 2). No significant change in total lung phospholipid content was observed in Lpla2⫺/⫺ and Lpla2⫹/⫹ 4-monthold mice. However, significant increases in both lung and lavage fluid phospholipid levels was seen in 12-month-old mice
(Table 2). When the levels of disaturated PC content were
measured, an increase that was proportionate to total phospholipid levels was observed in both the Lpla2⫺/⫺ mouse lung
and lavage fluid.
There was no significant difference in body and organ
weights between the Lpla2 genotypes at 4 months of age. A
routine histological survey of their organs, including the hearts,
livers, kidneys, brains, and spleen, by hematoxylin and eosin
staining showed no gross differences between wild-type and
homozygous mice at 4 and 12 months of age (data not shown).
However, periodic acid-schiff staining of the organs revealed
the presence of foam cells throughout these organs in the
homozygous null mice that was most apparent in the spleens of
the 1-year-old mice (Fig. 3C and D). By 12 months of age,
however, significant splenomegaly was observed in the Lpla2⫺/⫺
mice (Fig. 5A). A greater than fourfold increase in spleen
weight was observed. Phospholipid analysis revealed that the
increase in phospholipid was primarily due to changes in phosphatidylcholine and phosphatidylethanolamine, consistent
with the known substrate specificity of LPLA2 (Fig. 5B and C).
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concentric lamellar bodies within cells and the intralysosomal
accumulation of phospholipids. Phospholipidosis occurs in a
variety of clinical settings. Phospholipidosis may be associated
with the exposure to xenobiotics. Drugs and their metabolites
that induce cellular phospholipid accumulation fall into many
different classes, including antiarrhythmics, antipsychotics,
antibiotics, and cholesterol-lowering agents. However, these
drugs share a common physiochemical structure that includes
a hydrophobic ring structure and hydrophilic side chain with a
charged cationic amine group (7). Phospholipidosis may also
occur in response to environmental exposures such as silica
(14). Finally, phospholipidosis is often used synonymously with
the term pulmonary alveolar proteinosis to describe the congenital or acquired disease associated with impaired surfactant
catabolism (18). Patients suffering from pulmonary alveolar

proteinosis present differently from those with drug-induced
phospholipidosis. Pulmonary alveolar proteinosis is characterized by a marked accumulation of surfactant lipid; drug-induced phospholipidosis is characterized by secondary inflammatory changes and long-term fibrosis. The consequences of
chronic exposure to cationic amphiphilic drugs are poorly understood, in large part due to the absence of a suitable animal
model for long-term evaluation (16). In particular, the relationship between the short-term development of lysosomal
phospholipid accumulation and long-term inflammation and
fibrosis has not been well studied. The Lpla2 knockout mouse
is a potentially useful model for elucidating this relationship.
Pulmonary alveolar proteinosis may also be associated with
the absence of functional surfactant protein B or loss of granulocyte-macrophage colony-stimulating factor (GM-CSF) ac-
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FIG. 3. Light microscopy of tissues from 1-year-old Lpla2⫹/⫹ and Lpla2⫺/⫺ mice. Panels A and B represent PAS staining of formalin-fixed
inflated lungs and of spleens from 1-year-old wild-type and Lpla2⫺/⫺ mice, respectively. The histology is noteworthy for increased numbers of
enlarged alveolar macrophages, as denoted by the arrows in the air spaces of the null mice and a mononuclear infiltrate surrounding the small
airways and arteries. Panels C and D represent PAS staining from the spleens of 1-year-old wild-type and Lpla2⫺/⫺ mice, respectively. PAS-positive
macrophages are denoted by the arrows.
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tivity (18). Although the latter is an important factor in alveolar macrophage differentiation, the relationship between loss
of GM-CSF and impaired catabolism of surfactant phospholipids is not well understood. Three histological features are
observed in the lungs of the GM-CSF knockout mouse. These

TABLE 2. Protein and phospholipid content of Lpla2⫺/⫺ and
Lpla2⫹/⫹ mouse lung and bronchoalveolar lavage fluid
Lpla2⫹/⫹

Lpla2⫺/⫺a

Total protein (mg/kg of
mouse wt)
Tissue
Lavage fluid

448.2 ⫾ 12.9
16.4 ⫾ 2.6

525.9 ⫾ 52.8*
16.1 ⫾ 7.5

Total phospholipid
(mol/kg mouse wt)
Tissue
Lavage fluid

118.9 ⫾ 8.8
16.2 ⫾ 1.5

155.4 ⫾ 14.9*
21.6 ⫾ 1.2**

Total disaturated PC
(mol/kg mouse wt)
Tissue
Lavage fluid

22.7 ⫾ 2.2
8.3 ⫾ 0.7

35.4 ⫾ 3.3**
11.2 ⫾ 0.7**

Total

31.0 ⫾ 2.9

46.6 ⫾ 4.0**

Measurement

a

* and ** denote P ⬍ 0.05 and P ⬍ 0.005, respectively (n ⫽ 4).

include the accumulation of surfactant in the airspaces, the
development of a foam cell phenotype by alveolar macrophages, and a peribronchial and perivascular inflammation.
Two of these findings, the foam cell phenotype and inflammation, are prominently found in the Lpla2⫺/⫺ mouse. Although
increased surfactant phospholipid could be detected in 1-yearold Lpla2⫺/⫺ mice, this was less robust a finding than that
observed in the GM-CSF knockout mouse. In prior work
where Lpla2 was found to be highly expressed in alveolar
macrophages, the GM-CSF knockout mouse was found to
have limited expression of Lpla2, and a GM-CSF transgenic
mouse was found to have increased expression of Lpla2 (1).
The present study is also consistent with the possibility that
Lpla2 mediates at least some of the GM-CSF-dependent
changes observed in the lung.
An additional finding, not reported in the GM-CSF knockout mouse, was the presence of splenomegaly. This finding is
consistent with that observed in another disorder of foam cell
formation, Gaucher disease. The basis for the splenomegaly is
unknown, but in a manner similar to Gaucher disease, it appears to be the result of secondary growth and not from the
increase in lipid mass per se. Like Gaucher disease, this finding
may be reflective of the role of the splenic macrophage in the
clearance of senescent erythrocytes. The Lpla2 null mouse may
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FIG. 4. Electron micrographs of alveolar macrophages (A and B) and peritoneal macrophages (C and D) obtained from 3-month-old Lpla2⫹/⫹
and Lpla2⫺/⫺ mice. (A and C) Lpla2⫹/⫹ mice; (B and D) Lpla2⫺/⫺ mice.
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be a useful tool for probing the mechanism behind the lipidinduced organomegaly.
In addition to the increased accumulation of surfactant
phospholipid in 1-year-old mice, including the accumulation of
disaturated PC, further confirmation for a role for Lpla2 in
surfactant degradation was based on the use of ESI/MS analysis of macrophages isolated from Lpla2 wild-type and null
mice. These analyses revealed that of the measured lipids, PC
and PE were most directly affected by the loss of Lpla2 activity.
Those species of PC containing saturated fatty acids, most
notably palmitate, as well as those with diacylglyceryl, plasmenyl, and plasmanyl linkages increased comparably in the absence of the acidic phospholipase A2 activity. These data suggest that Lpla2 does not discriminate among PCs with different
aliphatic chains. By contrast, sphingomyelin and phosphatidic
acid levels were not increased, consistent with the known substrate specificity of Lpla2.
A small change in ceramide content was observed. Lpla2 was
originally identified as a 1-O-acylceramide synthase (3). This
increase in ceramide may reflect the loss of this activity. However, the physiological role of Lpla2 as a regulator of ceramide
metabolism remains to be clarified and is not obvious from the
present study. Nevertheless, Lpla2 activity was measured in the
wild-type and knockout mice using both ceramide and water as
acceptors for the enzyme activity. By assaying Lpla2 as either a

1-O-acylceramide synthase or as a phospholipase A2, the enzyme activity was abolished to greater than 95% in the lungs
and alveolar macrophages of the knockout mice, suggesting
that Lpla2 represents the primary acidic phospholipase A2
activity found in lung.
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